drugset
drugset / Trial / NCT04441450

ADME Study of [14C]ICP-022 in Healthy Males

NCT04441450 ↗

Completed 6 enrolled Beijing InnoCare Pharma Tech Co., Ltd.
NaSingle-groupOpen-labelOther

Summary

The purpose of this study is to investigate the absorption, the metabolic pathways and the excretion of ICP-022 in healthy male adult participants after administration of a single oral dose of 150 mg of 14C ICP-022.

Timeline

Start
2019-07-01
Primary completion
2019-08-06
Completion
2019-08-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Orelabrutinib Small molecule 150 mg Oral

Indications

No indication recorded.